Galunisertib, an oral, small molecule inhibitor of TGF‐β‐receptor I (ALK5), interferes with TGF‐β signaling and is deleterious to HCC in vitro and in vivo.13 Here, TGFB1 is linked to hepatocellular carcinoma.